Zevra Therapeutics, Inc. (ZVRA)
$10.23-1.54%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $605M
- Beta
- 0.98
- P/E (TTM)
- 10.65
- Short % float
- 13.01%
- Days to cover
- 7.2
- SI change
- +24.6%
- 1W
- -7.67%
- 1M
- -12.19%
- vs SPY 1W
- -6.69%
- vs SPY 1M
- -14.05%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$13.6BRECOVERYQ 16$135.13+0.58%
- JAZZSELLJazz Pharmaceuticals plc$13.2BBEARQ 24$210.39-0.35%
- PRAXSELLPraxis Precision Medicines, Inc.$6.8BCRISISQ 10$243.34-1.78%
- ALKSSELLAlkermes plc$6.7BCRISISQ 6$39.73-1.64%
- XENESELLXenon Pharmaceuticals Inc.$3.3BCRISISQ 22$34.42-1.51%
- SUPNSELLSupernus Pharmaceuticals, Inc.$2.4BRECOVERYQ 26$42.01-4.36%
- GHRSSELLGH Research PLC$1.3BCRISISQ 14$18.85-1.54%
- ANROSELLAlto Neuroscience, Inc.$775MCRISISQ 14$22.09-1.72%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on ZVRA?
- LOPJLB’s latest quantitative signal on Zevra Therapeutics, Inc. (ZVRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ZVRA in?
- Zevra Therapeutics, Inc. (ZVRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Zevra Therapeutics, Inc. (ZVRA) do?
- Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily…